Any immunodeficiency | 36 (8.9%) | 93 (23.2%) | 179 (44.6%) | 179 (44.6%) | 179 (44.6%) |
Primary immunodeficiency | 29 (7.2%) | 83 (20.7%) | 158 (39.4%) | 158 (39.4%) | 158 (39.4%) |
Isolated IgG subclass deficiency | 0 | 0 | 36 (9%) | 36 (9%) | 36 (9%) |
| 0 | 0 | 3 (0.8%) | 3 (0.8%) | 3 (0.8%) |
| 0 | 0 | 2 (0.5%) | 2 (0.5%) | 2 (0.5%) |
| 0 | 0 | 6 (1.5%) | 6 (1.5%) | 6 (1.5%) |
| 0 | 0 | 24 (5.9%) | 24 (5.9%) | 24 (5.9%) |
| 0 | 0 | 1 (0.2%) | 1 (0.2%) | 1 (0.2%) |
Isolated IgM deficiency | 0 | 0 | 3 (0.7%) | 3 (0.7%) | 3 (0.7%) |
Unclassified antibody deficiency | 0 | 0 | 6 (1.5%) | 6 (1.5%) | 6 (1.5%) |
CVID | 0 | 0 | 2 (0.5%) | 2 (0.5%) | 2 (0.5%) |
Severe combined immunodeficiency | 0 | 0 | 0 | 0 | 0 |
Combined immunodeficiency | 0 | 0 | 0 | 0 | 0 |
Hyper-IgE syndrome | 0 | 0 | 0 | 0 | 0 |
Isolated IgA deficiency | 2 (0.5%) | 2 (0.5%) | 2 (0.5%) | 2 (0.5%) | 2 (0.5%) |
DiGeorge Syndrome | 1 (0.2%) | 1 (0.2%) | 1 (0.2%) | 1 (0.2%) | 1 (0.2%) |
Unclassified immunodeficiency | 26 (6.5%) | 80 (20%) | 108 (26.9%) | 108 (26.9%) | 108 (26.9%) |
Secondary immunodeficiency | 7 (1.7%) | 10 (2.5%) | 21 (5.2%) | 21 (5.2%) | 21 (5.2%) |
Immunosuppressive drugs | 1 (0.2%) | 3 (0.7%) | 11 (2.7%) | 11 (2.7%) | 11 (2.7%) |
| 1 (0.2%) | 3 (0.7%) | 8 (2%) | 8 (2%) | 8 (2%) |
| 0 (0%) | 0 (0%) | 2 (0.5%) | 2 (0.5%) | 2 (0.5%) |
| 0 (0%) | 0 (0%) | 1 (0.2%) | 1 (0.2%) | 1 (0.2%) |
Haematological malignancy | 6 (1.5%) | 6 (1.5%) | 7 (1.7%) | 7 (1.7%) | 7 (1.7%) |
Transplant | 0 | 1 (0.2%) | 3 (0.7%) | 3 (0.7%) | 3 (0.7%) |
Other aetiologies | 113 (28.2%) | 113 (28.2%) | 67 (16.7%) | 67 (16.7%) | 67 (16.7%)# |
Idiopathic bronchiectasis | 252 (62.8%) | 195 (48.6%) | 155 (38.7%) | 155 (38.7%) | 155 (38.7%) |
Treatable immunodeficiencies | 15 (3.7%) | 37 (9.2%) | 67 (16.7%) | 67 (16.7%) | 67 (16.7%) |